Galectin up on positive review from meeting for lead drug's trial

Galectin Therapeutics

06/10/2022 18:59

** Shares of Galectin Therapeutics Inc  GALT.O  up ~2% at
$1.65
    ** Company reports positive outcome from second data and
safety monitoring board meeting for its lead experimental drug's
trial, testing it for treating a type of liver cirrhosis-related
complication  urn:newsml:reuters.com:*:nGNX24d4cK 
    ** Says the board has concluded that trial can continue as
designed, without modifications
    ** Drug is being evaluated in patients with liver cirrhosis
caused by non-alcoholic steatohepatitis (NASH)
    ** Co plans to fully enroll the study around year-end
    ** Including session's gain, stock down ~20% YTD
 (Reporting by Raghav Mahobe)
 ((Raghav.Mahobe@thomsonreuters.com;))